We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment.
- Authors
Hill, Matthew N.; Carrier, Erica J.; McLaughlin, Ryan J.; Morrish, Anna C.; Meier, Sarah E.; Hillard, Cecilia J.; Gorzalka, Boris B.
- Abstract
It has been suggested that disturbances in endocannabinoid signaling contribute to the development of depressive illness; however, at present there is insufficient evidence to allow for a full understanding of this role. To further this understanding, we performed an analysis of the endocannabinoid system in an animal model of depression. Male rats exposed to chronic, unpredictable stress (CUS) for 21 days exhibited a reduction in sexual motivation, consistent with the hypothesis that CUS in rats induces depression-like symptoms. We determined the effects of CUS, with or without concurrent treatment with the antidepressant imipramine (10 mg/kg), on CP55940 binding to the cannabinoid CB1 receptor; whole tissue endocannabinoid content; and fatty acid amide hydrolase (FAAH) activity in the prefrontal cortex, hippocampus, hypothalamus, amygdala, midbrain and ventral striatum. Exposure to CUS resulted in a significant increase in CB1 receptor binding site density in the prefrontal cortex and a decrease in CB1 receptor binding site density in the hippocampus, hypothalamus and ventral striatum. Except in the hippocampus, these CUS-induced alterations in CB1 receptor binding site density were attenuated by concurrent antidepressant treatment. CUS alone produced a significant reduction in N-arachidonylethanolamine (anandamide) content in every brain region examined, which was not reversed by antidepressant treatment. These data suggest that the endocannabinoid system in cortical and subcortical structures is differentially altered in an animal model of depression and that the effects of CUS on CB1 receptor binding site density are attenuated by antidepressant treatment while those on endocannabinoid content are not.
- Subjects
CANNABINOIDS; ANTIDEPRESSANTS; ANHEDONIA; MENTAL depression; PSYCHOLOGICAL stress; HYPOTHALAMIC-pituitary-adrenal axis; GLUCOCORTICOIDS
- Publication
Journal of Neurochemistry, 2008, Vol 106, Issue 6, p2322
- ISSN
0022-3042
- Publication type
Article
- DOI
10.1111/j.1471-4159.2008.05567.x